J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Journal ArticleDOI
Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer.
Patrick M. Forde,Kellie N. Smith,Jamie E. Chaft,Matthew D. Hellmann,Taha Merghoub,Jedd D. Wolchok,Stephen C. Yang,Richard J. Battafarano,Edward Gabrielson,Christos S. Georgiades,Gary L. Rosner,Valsamo Anagnostou,Victor E. Velculescu,Suzanne L. Topalian,Drew M. Pardoll,Julie R. Brahmer +15 more
TL;DR: Nivolumab is an anti-PD1 immune checkpoint blocker which has demonstrated durable responses and improved survival vs. second-line chemotherapy in metastatic non-small-cell lung cancer patients.
Journal ArticleDOI
Hiding the road signs that lead to tumor immunity.
TL;DR: Mechanisms of immune evasions by tumors, including the recent finding that CCL2 nitrosylation prevents T cell infiltration into tumors, are discussed.
Journal ArticleDOI
CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma.
Antoni Ribas,F. Stephen Hodi,John F. Kurland,Vafa Shahabi,Stephen Francis,Cyril Konto,Andrew K. Joe,Ioannis Lainas,Jedd D. Wolchok +8 more
TL;DR: Ipilimumab significantly improved the ability of this monoclonal antibody to block cytotoxic T-lymphocyte antigen-4 (CTLA-4) to augment antitumor immune responses in mice treated with EMT.
Journal ArticleDOI
A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC).
Adi Diab,Stephen B. Solomon,Christopher Comstock,Majid Maybody,Virgilio Sacchini,Jeremy C. Durack,Brian Blum,Jianda Yuan,Sujata Patil,Deirdre Neville,Janice S. Sung,Alan Kotin,Elizabeth A. Morris,Edi Brogi,Monica Morrow,Jedd D. Wolchok,James P. Allison,Clifford A. Hudis,Larry Norton,Heather L. McArthur +19 more
TL;DR: The safety of pre-op cryo and/or ipi (10mg/kg) in pts with ESBC is evaluated and if at least 5/6 pts in each group proceed with surgery without delay, the regimen will be considered safe/tolerable.
Journal ArticleDOI
Patient perspectives on ipilimumab across the melanoma treatment trajectory
Elyse Shuk,Alexander N. Shoushtari,Alexander N. Shoushtari,Jason J. Luke,Michael A. Postow,Michael A. Postow,Maggie Callahan,Maggie Callahan,James J. Harding,James J. Harding,Katherine G. Roth,Marisa Flavin,Adrian Granobles,Jana Christian,Geoffrey S. Gold,Maria Schoenhammer,Mallorie Gordon,Nicholas Cimaglia,Robert Dyson,Noah Goodman-Davis,Marta N. Colgan,Itisha S. Jefferson,Rodrigo Ramella Munhoz,Sandra P. D'Angelo,Sandra P. D'Angelo,Jedd D. Wolchok,Jedd D. Wolchok,Paul B. Chapman,Paul B. Chapman,Ping Chi,Ping Chi,Richard D. Carvajal,Jennifer L. Hay +32 more
TL;DR: Patients generally regarded ipilimumab positively despite the risk of unique toxicities and potential for delayed therapeutic responses; however, those with progression expressed uncertainty regarding whether taking ipILimumab was worthwhile.